As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a study of long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial.
Independent expert commentary is provided by Clinical Associate Professor Saxon Smith, a consultant dermatologist in private practice in Gosford and St Leonards.
Please login below to download this issue (PDF)